Allergic rhinitis and COVID-19: friends or foes?

Gani, Federica; Cottini, M.; Landi, Massimo; Berti, Alvise; Comberiati, Pasquale; Peroni, Diego; Senna, Gianenrico; Lombardi, Carlo

doi:10.23822/eurannaci.1764-1489.234

Cited by 19 publications

(23 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chi square testing showed a significant difference between the AR and control groups in age and asthma diagnosis. scores indicating minimal anxiety (0-4), mild anxiety (5-9), moderate anxiety (10)(11)(12)(13)(14), and severe anxiety (15)(16)(17)(18)(19)(20)(21). 20 Participants meeting diagnostic criteria for GAD are indicated by the red boxes (GAD-7 score≥10).…”

Section: Case-control Analysismentioning

confidence: 99%

“…Although there is emerging evidence that AR is not associated with poorer COVID-19 prognosis, AR patients may have suffered negative psychological consequences from an increased perceived COVID-19 risk. 11 Compounded with a potential underlying AR-anxiety relationship, these COVID-19-specific concerns may put AR patients at particular risk for increased pandemic-time anxiety.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anxiety in adults with allergic rhinitis during the coronavirus disease 2019 pandemic: A Canadian perspective

Linton

Sunavsky

et al. 2022

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Section: Case-control Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Anxiety in adults with allergic rhinitis during the coronavirus disease 2019 pandemic: A Canadian perspective

Linton

Sunavsky

et al. 2022

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

“…In a nationwide study performed in Korea, allergic rhinitis brought about an elevated risk of susceptibility to COVID-19 infection and poorer prognosis of COVID-19 [113]. In contrast, in a study carried out in Turkey [114] and in another conducted in Italy [115], the severity of COVID-19 was not influenced by allergic rhinitis.Pediatric allergic rhinitis may be accompanied with a milder course of COVID-19 disease [116]. In Chinese patients, allergic rhinitis did not affect COVID-19 mortality.…”

Section: Arnd Prevented Fibrosis Of Calu-3 Cellsmentioning

confidence: 92%

An anti-inflammatory and anti-fibrotic proprietary Chinese medicine nasal spray designated as Allergic Rhinitis Nose Drops (ARND) with potential to prevent SARS-CoV-2 coronavirus infection by targeting RBD (Delta)- angiotensin converting enzyme 2 (ACE2) binding

Yip

Lee

et al. 2022

Chin Med

View full text Add to dashboard Cite

Background Since the outbreak of COVID-19 has resulted in over 313,000,000 confirmed cases of infection and over 5,500,000 deaths, substantial research work has been conducted to discover agents/ vaccines against COVID-19. Undesired adverse effects were observed in clinical practice and common vaccines do not protect the nasal tissue. An increasing volume of direct evidence based on clinical studies of traditional Chinese medicines (TCM) in the treatment of COVID-19 has been reported. However, the safe anti-inflammatory and anti-fibrotic proprietary Chinese medicines nasal spray, designated as Allergic Rhinitis Nose Drops (ARND), and its potential of re-purposing for suppressing viral infection via SARS-CoV-2 RBD (Delta)- angiotensin converting enzyme 2 (ACE2) binding have not been elucidated. Purpose To characterize ARND as a potential SARS-CoV-2 entry inhibitor for its possible preventive application in anti-virus hygienic agent. Methods Network pharmacology analysis of ARND was adopted to asacertain gene targets which were commonly affected by COVID-19. The inhibitory effect of ARND on viral infection was determined by an in vitro pseudovirus assay. Furthermore, ARND was confirmed to have a strong binding affinity with ACE2 and SARS-CoV-2 spike-RBD (Delta) by ELISA. Finally, inflammatory and fibrotic cell models were used in conjunction in this study. Results The results suggested ARND not only inhibited pseudovirus infection and undermined the binding affinity between ACE2 and the Spike protein (Delta), but also attenuated the inflammatory response upon infection and may lead to a better prognosis with a lower risk of pulmonary fibrosis. The data in this study also provide a basis for further development of ARND as an antiviral hygienic product and further investigations on ARND in the live virus, in vivo and COVID-19 patients. ARND holds promise for use in the current COVID-19 outbreak as well as in future pandemics. Conclusion ARND could be considered as a safe anti-SARS-CoV-2 agent with potential to prevent SARS-CoV-2 coronavirus infection. Graphical abstract

show abstract

“…Allergic rhinitis (AR) is a chronic respiratory allergic disease mediated by IgE that is characterized by the clinical symptoms of sneezing, itching, rhinorrhea and nasal blockage. It affects 10-40% of the population, approximately one billion people worldwide [1]. The prevalence of AR in European adults was reported to range from 17% to 28.5% [2].…”

Section: Introductionmentioning

confidence: 99%

A novel and alternative therapy for persistent allergic rhinitis via intranasal acupuncture: a randomized controlled trial

Liu

Gong

Tang³

et al. 2023

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Background Acupuncture is used to treat allergic rhinitis (AR) in traditional Chinese medicine, and the ST2 and ST36 acupoints are generally selected in clinical practice. We report a new intranasal acupuncture method at the Neiyingxiang (EX-HN9) and Biqiu points for the treatment of persistent AR (PAR). Here, the efficacy and safety of this method were evaluated. Methods A total of 120 patients diagnosed with PAR were randomly allocated (2:1 ratio) to intranasal acupuncture or Western medicine groups, the basic principle of random grouping is SAS random grouping method. The applicator held a nasal endoscope and a 0.30 × 75 mm filiform needle in their left and right hands, respectively. When aiming at the Neiyingxiang or Biqiu point, the applicator quickly inserted the needle to a 20-mm depth as parallel as possible to the inferior turbinate or middle turbinate, without special reinforcing and reducing techniques (the needle remained for 20 min). The intranasal acupuncture groups received acupuncture treatment three times per week for 2 weeks. The Western medicine group was treated with budesonide nasal spray (two sprays/nostril, twice/day) and loratadine (one tablet/night) for 2 weeks. Visual analog scale (VAS) scores were the primary outcome. Quality of life, medication dosages and adverse events were secondary outcomes measured using the Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ). Confidence assessments were performed to evaluate data from the treatment and follow-up periods. Results The results were as follows: (1) VAS and RQLQ scores were significantly lower in the intranasal acupuncture group than in the Western medicine group on day 1 (i.e., first treatment) (P < 0.05; 95% CI − 13.1 to − 9.6 VAS points) (P < 0.05; 95% CI − 20.27 to − 12.28 RQLQ points). Overall symptoms (95% CI − 2.86 to − 1.86 points), nasal obstruction (95% CI − 6.33 to − 5.36 points), olfactory function (95% CI − 2.91 to − 1.75 points), sleep (95% CI − 5.05 to − 3.57 points), actual problems (95% CI − 2.03 to − 0.06 points), nasal symptoms (95% CI − 6.62 to − 4.5 points), and emotional problems (95% CI − 5.05 to − 3.5 points) were significantly improved. (2) VAS and RQLQ scores in the two groups were significantly improved at week 2; however, there were no significant group differences in the VAS (P > 0.05; 95% CI − 1.21 to − 1.38 points) and RQLQ (P > 0.05; 95% CI − 0.33 to − 3.46 points) scores. Olfactory function symptoms were significantly improved (95% CI − 1.58 to − 0.21 points). (3) During the follow-up period, there was a significant difference between the two groups (P < 0.05) with higher RQLQ and VAS scores in the intranasal acupuncture group than in the Western medicine group. VAS scores on rhinobyon symptoms, nasal itch, rhinorrhea and olfactory function and RQLQ scores for activities, non-nasal/eye symptoms, actual problems, nasal symptoms, and eye symptoms were significantly improved. (4) No adverse events were observed in either group during treatment. Conclusions Intranasal acupuncture has good efficacy and safety in the treatment of PAR. Moreover, VAS and RQLQ scores were much lower in the intranasal acupuncture group than in the Western medicine group, and acupuncture had an immediate impact, especially for improving nasal congestion, olfactory function and sleep.

show abstract

Allergic rhinitis and COVID-19: friends or foes?

Cited by 19 publications

References 44 publications

Anxiety in adults with allergic rhinitis during the coronavirus disease 2019 pandemic: A Canadian perspective

Anxiety in adults with allergic rhinitis during the coronavirus disease 2019 pandemic: A Canadian perspective

An anti-inflammatory and anti-fibrotic proprietary Chinese medicine nasal spray designated as Allergic Rhinitis Nose Drops (ARND) with potential to prevent SARS-CoV-2 coronavirus infection by targeting RBD (Delta)- angiotensin converting enzyme 2 (ACE2) binding

A novel and alternative therapy for persistent allergic rhinitis via intranasal acupuncture: a randomized controlled trial

Contact Info

Product

Resources

About